Abstract
Vortioxetine (Brintellix®), a serotonin transporter inhibitor and modulator of serotonin receptor activity, extends the available options for treating major depressive disorder (MDD). It is generally effective as acute treatment (including in elderly patients), in relapse prevention and as maintenance treatment in patients with MDD. Vortioxetine improves cognitive function in patients with MDD and is generally well tolerated.
Similar content being viewed by others
References
Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol. 2013;16(6):1433–42.
Pehrson AL, Leiser SC, Gulinello M, et al. Treatment of cognitive dysfunction in major depressive disorder-a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur J Pharmacol. 2015;753:19–31.
Brintellix® (vortioxetine tablets): EU summary of product characteristics. London: European Medicines Agency; 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf.
Brintellix® (vortioxetine tablets): US prescribing information. Deerfield: Takeda Pharmaceuticals America, Inc.; 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf.
Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206–21.
Areberg J, Luntang-Jensen M, Søgaard B, et al. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol. 2012;110(4):401–4.
Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol. 2013;23(10):1190–8.
Sánchez C, Pehrson AL, Bétry C, et al. Vortioxetine (Lu AA21004), an investigational multimodal antidepressant: differentiation from currently used antidepressants in preclinical rodent models [abstract]. Biol Psychiatry. 2013;9(Suppl 1):106S–7S.
Sánchez C. Lu AA21004, a novel multimodal antidepressant. Neurotherapeutics. 2012;9(3):681–2.
Li Y, Raaby KF, Sánchez C, et al. Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behav Brain Res. 2013;256:520–8.
Browning M, Smith J, Cohen S, et al. Vortioxetine reduces BOLD signal during performance of the N-back task in subjects remitted from depression and healthy control participants [abstract no. W12]. In: 53rd Annual Meeting of the American College of Neuropsychopharmacology. 2014.
Dawson G, Conen S, McKie S, et al. Effects of vortioxetine on resting-state activity in spbjects remitted from depression and healthy controls [abstract no. M155]. In: 53rd Annual meeting of the American College of Neuropsychopharmacology. 2014.
Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16(2):313–21.
Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15(5):589–600.
Mahableshwarkar AR, Jacobsen PL, Chen Y, et al. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl). 2015. doi:10.1007/s00213-014-3839-0.
Nishimura A, Hirochi K, Asari K, et al. A multinational, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine 5, 10, and 20 mg in adults with major depressive disorder [abstract no. 106]. In: 27th Annual US Psychiatric and Mental Health Congress. 2014.
Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73(7):953–9.
Jacobsen P, Mahableshwarkar AR, Serenko M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder [abstract no. NR9-06]. In: 166th Annual Meeting of the American Psychiatric Association. 2013.
Mahableshwarkar A, Jacobsen PL, Serenko M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder [abstract no. NR9-02]. In: 166th Annual Meeting of the American Psychiatric Association. 2013.
Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482–91.
Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138–49.
Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29(3):217–26.
McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557–67.
Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015. doi:10.1038/npp.2015.52.
Vieta E, Loft H, Mahableshwarkar A, et al. The efficacy of vortioxetine in the treatment of patients with major depressive disorder (MDD) in short-term placebo-controlled studies: a meta-analysis of 11 studies [abstract no. P.2.f.023]. Eur Neuropsychopharmacol. 2014;24(Suppl 2):S465–6.
US National Institutes of Health. ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 12 May 2015.
Baldwin D, Loft H, Jacobsen P, et al. The efficacy of vortioxetine in treating patients with severe depression or with depression and high level of anxiety symptoms [abstract no. P.2.f.020]. In: 27th European College of Neuropsychopharmacology Congress. 2014.
Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–23.
Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012;28(10):1717–24.
Filippov G, Christens PF. Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder [abstract no. P.2.b.011]. Eur Neuropsychopharmacol. 2013;23(Suppl 2):S325.
Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2013;29(1):36–44.
Jacobsen P, Harper L, Serenko M, et al. A phase 3, long-term, open-label extension study evaluating the safety and tolerability of 15 and 20 mg vortioxetine in subjects with major depressive disorder [abstract no. P-23-017]. Int J Neuropsychopharmacol. 2014;17(Suppl 1):97–8.
Florea I, Dragheim M, Loft H. The multimodal antidepressant Lu AA21004: open-label long-term safety and tolerability study in major depressive disorder [abstract no. P.2.c.010]. Eur Neuropsychopharmacol. 2012;22(Suppl 2):S255–6.
Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenalin reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29(5):470–82.
Wang G, Gislum M, Filippov G, et al. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study. Curr Med Res Opin. 2015;31(4):785–94.
Boulenger J-P, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol (Oxf). 2012;26(11):1408–16.
Jacobsen P, Mahableshwarkar AR, Chen Y, et al. Vortioxetine versus escitalopram in adults with well-treated major depressive disorder experiencing treatment-emergent sexual dysfunction [abstract no. P.2.f.022]. Eur Neuropsychopharmacol. 2014;24(Suppl 2):S464–5.
Jacobsen P, Clayton A, Mahableshwarkar A, et al. The effect of vortioxetine in sexual dysfunction in adults with major depressive disorder or generalized anxiety disorder [abstract no. 35]. In: The American Society of Clinical Psychopharmacology Annual Meeting. 2014.
Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs. 2014;28(9):855–74.
Acknowledgments
The manuscript was reviewed by: M. Hahn, Vitos Rheingau, Eltville, Germany; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India.
Disclosure
This article was updated from CNS Drugs 2014;28(9):855–74 [39] by salaried employees of Adis/Springer. The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the authors on the basis of scientific merit.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Garnock-Jones, K.P., Lyseng-Williamson, K.A. Vortioxetine in major depressive disorder: a guide to its use in the EU. Drugs Ther Perspect 31, 221–228 (2015). https://doi.org/10.1007/s40267-015-0217-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-015-0217-x